[Jiangsu News] Taiwan has finally purchased the new coronavirus vaccine. 20 million doses of the vaccine are expected to arrive in March next year.

[Jiangsu News] Taiwan has finally purchased the new coronavirus vaccine. 20 million doses of the vaccine are expected to arrive in March next year.

has purchased a total of nearly 20 million doses of the new crown vaccine in connection with

Taipei Zhongshi Electronic News, Chen Shizhong, commander of the Taiwan Central Epidemic Command Center, announced on the 30th that as of now, the total number of new crown vaccines in connection with the purchase of nearly 20 million doses, including about 4.76 million doses of the new crown vaccine purchased from the COVAX mechanism (WHO COVID-19 Vaccine Implementation Plan), 10 million doses of the vaccine developed by Astertellicon Pharmaceuticals and Oxford University, and another is under negotiation; in addition, it is currently continuing to negotiate with several vaccine manufacturers conducting Phase 3 clinical trials. The expected fastest supply time is March 2021, and the cold chain system required for the vaccine has also been planned.

Command Center stated that in order to enable the vaccine to exert the benefits of herd immunity, the Command Center plans to purchase doses that cover about 65% of the population. It is estimated that 30 million doses of vaccines will be purchased based on the 2 doses per person. It is expected to purchase 30 million doses of vaccines, and 13.58 million people will be given priority to the public expenses. First, medical personnel will be given the highest priority. Second, central and local government epidemic prevention personnel, including airport CIQS personnel, third, necessary personnel to maintain social operations such as police and military police, fourth, caregivers, caregivers and staff of long-term care institutions such as maintenance, maintenance, day care, and social welfare, and fifth military personnel.

As for elderly people over 65 years old, the sixth priority is to vaccinate, the seventh, those aged 19 to 64 who have high-risk diseases that are prone to serious diseases, the eighth is patients with rare diseases and major injuries, and the last one is adults aged 50 to 64. The command center also stated that it will continue to closely purchase vaccines that are sufficient to meet the needs of the people through diverse channels. In the future, it will also adjust the situation in Taiwan, the number of vaccines obtained and the applicable targets, and at the same time evaluate the opening of the self-funded vaccination plan for people with emergency special needs.

vaccine acquisition adopts "three-legged walk"

Command Center pointed out that based on the continued severe global epidemic and the continuous rekindling trend, vaccines are urgent and necessary prevention and control strategies for Taiwan's subsequent epidemic prevention and control and public protection. The vaccine is still a seller's market at this stage. The command center adopts diversified plans such as "international investment" (participating in the COVAX mechanism led by WHO, GAVI, and CEPI), "directly negotiated manufacturer purchases" and "self-made on the island" to disperse risks, obtain safe and effective vaccines as soon as possible, and provide the use of risk groups on the island.

Command Center said that due to the urgent overseas epidemic, some countries have begun to use emergency authorized COVID-19 vaccines due to the severe epidemic. However, there are still many undetermined risks of large-scale vaccination in communities. The command center will continue to collect overseas vaccine administration status and response methods to better understand the safety and effectiveness of vaccines, and at the same time formulate practical operation guidelines and deployment plans for vaccination on the island.

Regarding the progress of clinical trials of three vaccine R&D manufacturers on the island that the outside world is concerned about, the command center said that Guoguang Company cannot decide the optimal dose based on the results of the first phase clinical trial, and it is recommended to re-execute the dose exploration clinical trial. High-end companies have the conditions to approve the implementation of the second phase clinical trial plan. Lianya Biotechnology Company expects to provide the first phase of complete test data in January next year and continue the review. (End)